Disambiguating the bisphosphonates

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1357-1359

  Van den wyngaert, T ^a   Huizing, M T ^a   Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID;

BONE METASTASIS; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERCALCEMIA; LETTER; MEDICAL LITERATURE; MULTIPLE MYELOMA; NOMENCLATURE; OSSIFYING MYOSITIS; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; MOLECULAR STRUCTURE; TERMINOLOGY AS TOPIC;

EID: 46249109581     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn356     Document Type: Letter

References (15)

1. Devogelaer JP. Clinical use of bisphosphonates. Curr Opin Rheumatol 1996; 8: 384-391.
2. Briner WW, Francis MD, Widder JS. The control of dental calculus in experimental animals. Int Dent J 1971; 21: 61-72.
3. Fleisch H. Bisphosphonates in bone disease. New York, NY: The Parthenon Publishing Group 1995.
4. Fleisch H, Russell RG, Bisaz S et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in Vitro and in vivo. Calcif Tissue Res 1968; 2 (Suppl): 10-10a.
5. Bassett GA, Donath A, Macagno F et al. Diphosphonates in the treatment of myositis ossificans. Lancet 1969; 2: 845.
6. Fleisch H, Russell RG, Francis MD, Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262-1264.
7. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34.
8. Melani C, Sangaletfi S, Barazzetta FM et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma, Cancer Res 2007; 67: 11438-11446.
9. Penel N, Dewas S, Doutrelant P et al. Cancer-associated hypercalcemia treated with intravenous diphosphonates: A survival and prognostic factor analysis. Support Care Cancer 2008; 16: 387-392.
10. The National Library of Medicine. Medical Subject Headings (MeSH®) http://www.nlm.nih.gov/pubs/factsheets/mesh.html (2 March 2008, date last accessed).
11. The National Library of Medicine. MeSH descriptor data for "bisphospnonates" http://www.nlm.nih.gov/cgi/mesh/2008/ MB_cgj?mode=&index=3995&view=expanded (2 March 2008, date last accessed).
12. Panico R, Powell W, Richer J. A guide to IUPAC nomenclature of organic compounds (recommendations 1993). Oxford: Blackwell Science 1993.
13. Wilberg N, Holleman A, Wilberg E. Holleman-Wiberg's inorganic chemistry, London: Academic Press 2001; 714-715.
14. Fox M, Whitesell J. Organic chemistry. London: Jones & Bartlett Publishers Inc. 1997; 463.
15. Van Gelder JM, Breuer E, Ornoy A et al. Anticalcitication and antiresorption effects of bisacylphosphonates. Bone 1995, 16: 511-520.